Emerging Metabolic Targets in the Therapy of Hematological Malignancies

Figure 2

Chemical structures of glycolytic inhibitors. 2-Deoxyglucose (2-DG) and 3-bromopyruvate (3-BrPA) have been both applied in preclinical studies in HMs [110, 113, 121], whereas (FX11 [3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxilic acid]) (FX11) and dichloroacetate (DCA) have been applied in different solid tumors [92, 96].